Abstract
We raise some issues with the study by Pearce et al. that examined the timelines of submissions for medicines to the Pharmaceutical Benefits Advisory Committee (PBAC) following recommendation by the Australian Drug Evaluation Committee (ADEC), now known as the Advisory Committee on Prescription Medicines (ACPM).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
